CollaGenex denied motion to prevent generic Periostat
CollaGenex Pharmaceuticals of the USA says that its motion seeking a temporary restraining order and a preliminary injunction in the US District Court for the Eastern District of New York had been denied.
As a result, the defendants IVAX Pharmaceuticals and CorePharma LLC can continue to market their copycat versions of Periostat (oxycycline hyclate), the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy the supporting tissues and by enhancing bone protein synthesis.
CollaGenex chief executive Colin Stewart said: "we intend to continue to prosecute these law suits and seek compensation for profits lost as a result of the sale of infringing products. Meanwhile, we remain fully committed to executing our plans to develop our dermatology business."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze